- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05135559
Исследование того, насколько хорошо Концизумаб действует на вас, если у вас есть гемофилия А или В с ингибиторами или без них (Explorer10)
Открытое исследование по изучению эффективности, безопасности и фармакокинетики профилактического применения концизумаба у детей младше 12 лет с гемофилией А или В с ингибиторами или без них
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Расширенный доступ
Контакты и местонахождение
Места учебы
-
-
-
Algiers, Алжир, 16000
- Haematology and Blood Bank Department
-
Constantine, Алжир, 25000
- CHU Constantine BEN BADIS/ Hematology department
-
-
-
-
-
Plovdiv, Болгария, 4002
- UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
-
Sofia, Болгария, 1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
-
Varna, Болгария, 9010
- UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
-
-
-
-
-
Banja Luka, Босния и Герцеговина, 78000
- University Clinical Center of Republic Srpska (545)
-
Tuzla, Босния и Герцеговина, 75000
- University Clinical Centre Tuzla
-
-
-
-
-
Athens, Греция, GR-11527
- Aghia Sophia Childrens' Hospital
-
Thessaloniki, Греция, GR 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
Thessaloniki, Греция, 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
-
-
-
Assam
-
Guwahati, Assam, Индия, 781032
- Guwahati Medical College
-
-
Gujarat
-
Surat, Gujarat, Индия, 395002
- Nirmal Hospital Pvt. Ltd.
-
-
Maharashtra
-
Kolhāpur, Maharashtra, Индия, 416005
- SSSH_Dept. of Clinical Haematology & Haemato Oncology
-
Mumbai, Maharashtra, Индия, 400012
- Seth GS Medical College & KEM Hospital
-
Mumbai, Maharashtra, Индия, 400022
- K.J Somaiya Hospital and Research Centre
-
Mumbai, Maharashtra, Индия, 400066
- MCGM - Comprehensive Thalassemia Care
-
Pune, Maharashtra, Индия, 411004
- Sahyadri Super Speciality Hospital
-
-
Odisha
-
Cuttack, Odisha, Индия, 753007
- S.C.B. Medical College
-
-
Rajasthan
-
Jaipur, Rajasthan, Индия, 302004
- J K Lon Hospital
-
-
Uttar Pradesh
-
Noida, Uttar Pradesh, Индия, 201303
- Post Graduate Institute of Child Health
-
-
Uttart Pradesh
-
Lucknow, Uttart Pradesh, Индия, 226014
- SGPGI
-
-
-
-
-
Barcelona, Испания, 08035
- Hospital Vall d'Hebron
-
Madrid, Испания, 28046
- Hospital Universitario La Paz
-
Málaga, Испания, 29009
- Hospital Regional Universitario de Málaga
-
-
Murcia
-
El Palmar, Murcia, Испания, 30120
- Hospital Virgen de la Arrixaca - Hematología
-
-
-
-
-
Catania, Италия, 95123
- A.O.U policlinico "G. Rodolico-San Marco"
-
Florence, Италия, 50134
- Dipartimento di Ematologia Univ. Firenze
-
Padova, Италия, 35128
- Azienda Ospedaliera di Padova _
-
Parma, Италия, 43126
- Azienda Ospedaliera-Universitaria Parma
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V6H 3V4
- BC Children's Hospital
-
-
Ontario
-
Hamilton, Ontario, Канада, L8N 3Z5
- McMaster Children's Hospital
-
-
-
-
-
Beirut, Ливан, 961
- Saint George Hospital University Medical Center
-
Tripoli, Ливан, 1434
- Hospital Nini
-
-
-
-
-
Vilnius, Литва, LT-08406
- Centre of Oncology and Hematology, Vilnius University
-
-
-
-
Kuala Lumpur
-
Kampung Baru, Kuala Lumpur, Малайзия, 50300
- Hospital Tunku Azizah
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Малайзия, 10450
- Hospital Pulau Pinang
-
-
Sarawak
-
Kuching, Sarawak, Малайзия, 93586
- Sarawak General Hospital
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Малайзия, 20400
- Hospital Sultanah Nur Zahirah
-
-
-
-
-
Oslo, Норвегия, 0372
- Klinisk forskningspost
-
-
-
-
-
Gdansk, Польша, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin, Польша, 20-093
- Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
-
Warsaw, Польша, 02-091
- Uniwersyteckie Centrum Kliniczne WUM
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Польша, 50-556
- Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
-
-
-
-
-
Bucharest, Румыния, 022328
- Clinic of Haematology, Fundeni Clinical Institute
-
Cluj-Napoca, Румыния, 400177
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Oradea, Румыния, 410469
- Spitalul Clinic Judetean De Urgenta Bihor
-
-
-
-
-
Skopje, Северная Македония, 1000
- PHI University Clinic for Children's Diseases Skopje
-
-
-
-
-
Birmingham, Соединенное Королевство, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Соединенное Королевство, BS2 8BJ
- University Hospitals Bristol & Weston NHS Foundation Trust
-
London, Соединенное Королевство, WC1N 3HR
- Great Ormond Street Hospital for Children
-
London, Соединенное Королевство, SE1 7EH
- Evelina London Children's Hospital - Haemophilia
-
-
-
-
California
-
San Diego, California, Соединенные Штаты, 92123
- Rady Childrens Hosp San Diego
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- University of Colorado Hospital
-
-
Florida
-
Orlando, Florida, Соединенные Штаты, 32806
- Arnold Palmer Children's Hospital
-
Orlando, Florida, Соединенные Штаты, 32827
- Nemours Child Orlando Hem/Onc.
-
-
Georgia
-
Augusta, Georgia, Соединенные Штаты, 30912
- Augusta Univ/Childrens Hosp-GA
-
Savannah, Georgia, Соединенные Штаты, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Childrens Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46260
- Indiana Hemophilia-Thromb Ctr
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, Соединенные Штаты, 70118
- Children's Hosp-New Orleans
-
-
Missouri
-
Kansas City, Missouri, Соединенные Штаты, 64108
- The Children's Mercy Hospital
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68114
- Children's Nebraska
-
-
North Carolina
-
Greenville, North Carolina, Соединенные Штаты, 27834
- ECU Sickle Cell Comp Clinic
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19134
- St Christopher Hosp for Child
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Cook Children's Hospital-Hematology-Oncology
-
Houston, Texas, Соединенные Штаты, 77030
- Texas Children's Hospital_Houston
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- Pediatrics Hematology/Oncology Clinic Battle Building
-
-
-
-
-
Bangkok, Таиланд, 10400
- Ramathibodi Hospital
-
Bangkok, Таиланд, 10330
- King Chulalongkorn Memorial Hospital_Bangkok_0
-
Bangkok, Таиланд, 10700
- Siriraj Hospital - Hematology and Oncology
-
Bangkok, Таиланд, 10330
- King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
-
-
Mueang Distirct,
-
Ubon Ratchathani, Mueang Distirct,, Таиланд, 34000
- Sunpasitthiprasong Hospital_Pediatrics Department
-
-
-
-
-
Adana, Турция (Туркие), 01130
- Acibadem Adana Hastanesi
-
Adana, Турция (Туркие), 01130
- Acıbadem Adana Hastanesi-Hematoloji
-
Izmir, Турция (Туркие), 35100
- Ege Universitesi Tip Fakultesi
-
Izmir, Турция (Туркие), 35100
- Ege Üniversitesi Hastanesi- Hematoloji
-
Samsun, Турция (Туркие), 55139
- Ondokuz Mayis University Medical Faculty Ped. Haematology
-
Samsun, Турция (Туркие), 55139
- Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
-
-
Beşevler/Ankara
-
Ankara, Beşevler/Ankara, Турция (Туркие), 06500
- Gazi University
-
Ankara, Beşevler/Ankara, Турция (Туркие), 06500
- Gazi Üniversitesi Hastanesi- Hematoloji
-
-
-
-
-
Chambéry, Франция, 73000
- Centre Hospitalier Metropole Savoie
-
Le Kremlin-Bicêtre, Франция, 94275
- Ap-Hp-Hopital de Bicetre-1
-
Paris, Франция, 75015
- AP-HP-HOPITAL NECKER_Service d'hématologie
-
-
-
-
-
Gothenburg, Швеция, 413 46
- Sahlgrenska US - Koagulationscentrum
-
-
-
-
-
Tallinn, Эстония, 13419
- Tallinn Children's Hospital
-
-
-
-
Gauteng
-
Parktown, Johannesburg, Gauteng, Южная Африка, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Kanagawa, Япония, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Saitama, Япония, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
-
Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.
-
For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.
-
For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)
- Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
-
For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)
- Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
- Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
-
For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention or related products.
- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- Ongoing or planned Immune Tolerance Induction treatment.
- History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Concizumab-naïve patients
Concizumab-naïve participants below 12 years of age at the time of consent/assent |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
|
Экспериментальный: Patients coming from compassionate use
Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807 |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of patient(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: Week 32
|
Measured in ng/mL |
Week 32
|
|
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: Week 32
|
Measured in nM |
Week 32
|
|
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: Week 32
|
Measured in ng/mL |
Week 32
|
|
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: Prior to the concizumab administration at week 20
|
Measured in ng/mL |
Prior to the concizumab administration at week 20
|
|
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
|
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Временное ограничение: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng*hr/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Генетические заболевания, врожденные
- Гематологические заболевания
- Нарушения свертывания крови
- Геморрагические расстройства
- Нарушения свертывания крови, наследственные
- Нарушения белковой коагуляции
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Гемики и лимфатические заболевания
- Гемофилия А
- сочетание
Другие идентификационные номера исследования
- NN7415-4616
- U1111-1247-7330 (Другой идентификатор: World Health Organization (WHO))
- 2020-000504-11 (Номер EudraCT)
- jRCT2031220097 (Идентификатор реестра: JAPIC)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .